Blockchain Registration Transaction Record

Okogen Acquires Ranpirnase Assets, Expands Antiviral Pipeline Across Multiple Therapeutic Areas

Okogen acquires ranpirnase assets from Orgenesis, expanding antiviral pipeline to treat conjunctivitis, respiratory viruses, and high-consequence pathogens with host-directed mechanism.

This acquisition matters because it represents a significant advancement in antiviral therapeutics with potential implications for public health across multiple disease areas. For patients suffering from acute infectious conjunctivitis, OKG-0303 could provide the first comprehensive treatment addressing both viral and bacterial causes, potentially reducing treatment complexity and improving outcomes. More broadly, ranpirnase's host-directed mechanism offers a promising approach to combating viral resistance, a growing problem with current antiviral therapies. The expansion into medical countermeasures for high-consequence pathogens like filoviruses addresses critical preparedness gaps for potential pandemic threats, while the dermatology and respiratory virus applications could benefit millions affected by common viral infections. This strategic move positions Okogen to address multiple unmet medical needs with a single therapeutic platform, potentially accelerating development timelines across different indications.